A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the heart can pump and dramatically improves survival, in what a paper describing the results calls "an unprecedented recovery of cardiac function."

Currently, heart failure is irreversible. In the absence of a heart transplant, most medical treatments aim to reduce the stress on the heart and slow the progression of the often-deadly disease.

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells. This discovery - published today, Dec. 9, in Nature Biotechnology - could unveil an entirely different understanding of the origins of cancer within the body, as well as offer groundbreaking insight into new treatment strategies that could target the growth of tumors in their earliest stages.

Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead 7/12/2024

Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition 7/12/2024

AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report 7/12/2024

Akebia Ends Deal With CSL Vifor, Unveils Hefty Price Tag for CKD Anemia Drug Vafseo 7/12/2024

PBMs and Big Pharma Play Blame Game for Inflated Prescription Drug Prices 7/12/2024

Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff 7/12/2024

FDA Decision Tracker: Novo’s Once-Weekly Insulin Icodec Rejected 7/12/2024

The Horner-Wadsworth-Emmons (HWE) reaction is a fundamental reaction in organic chemistry, widely used to create conjugated carbonyl compounds. Conjugated carbonyl compounds are used in many industries for synthesizing perfumes, plastics, and pharmaceuticals and are also involved in biological processes. Consequently, methods for improving HWE reactions are an active area of research.

One potential application of HWE reactions is to develop (E)-isomers of conjugated carbonyl compounds that are useful for synthesizing chemicals called hynapene analogues with promising anti-cancer properties.

GSK plc (LSE/NYSE: GSK) and Medicines for Malaria Venture (MMV) announced that the World Health Organization (WHO) has awarded prequalification to tafenoquine, the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria. Tafenoquine, co-administered with chloroquine, is now also included in WHO's updated Guidelines for malaria, in South America, marking the first time the medicine has been recommended by WHO. This milestone is a significant step toward closing the treatment gap for P. vivax malaria.

A new study led by Lund University in Sweden has solved a years-old mystery: which patients with aggressive breast cancer are helped by a targeted cancer treatment that had been under development but was shelved. The study is important since it brings hope that the development of the drug can continue and that it will make it all the way to these patients.

Despite the efforts of the North American researchers, many years of research and development and millions of dollars spent, a medicine named ganitumab that had shown promising results against breast cancer in animal trials was shelved.

EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm 4/12/2024

EC Approves Illumina’s Plan to Divest Cancer Diagnostics Maker Grail 4/12/2024

AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates 4/12/2024

Enlivex’s Stock Plummets 50% on Phase II Sepsis Results for Cell Therapy 4/12/2024

Lilly Suffers Legal Loss in Tirzepatide Case Against Compounding Pharmacy 4/12/2024

AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma 4/12/2024

Fujifilm Pumps $1.2B into CDMO Capacity in North Carolina, Eyes 680 New Jobs by 2031 4/12/2024

Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACR 4/12/2024